Analysts Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Target Price at $187.71

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) have received a consensus rating of “Moderate Buy” from the fourteen brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $187.71.

Several analysts recently weighed in on JAZZ shares. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. Truist Financial raised their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the company from $145.00 to $179.00 in a research note on Friday, March 7th. Royal Bank of Canada cut their price target on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 26th. Finally, Cantor Fitzgerald lowered Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and lifted their price target for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $138.76 on Wednesday. The stock’s 50-day simple moving average is $131.41 and its 200 day simple moving average is $121.61. The firm has a market capitalization of $8.43 billion, a PE ratio of 19.54, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals has a twelve month low of $99.06 and a twelve month high of $148.06.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 4,813 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.42, for a total value of $695,093.46. Following the completion of the sale, the chief accounting officer now directly owns 8,237 shares in the company, valued at approximately $1,189,587.54. The trade was a 36.88 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CMO Robert Iannone sold 7,080 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $138.60, for a total value of $981,288.00. Following the completion of the sale, the chief marketing officer now owns 82,024 shares of the company’s stock, valued at approximately $11,368,526.40. The trade was a 7.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 28,736 shares of company stock worth $4,022,825 over the last ninety days. 4.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Jazz Pharmaceuticals by 22.1% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,102 shares of the specialty pharmaceutical company’s stock valued at $505,000 after acquiring an additional 743 shares in the last quarter. Mackenzie Financial Corp increased its holdings in shares of Jazz Pharmaceuticals by 493.3% during the fourth quarter. Mackenzie Financial Corp now owns 20,286 shares of the specialty pharmaceutical company’s stock valued at $2,498,000 after acquiring an additional 16,867 shares in the last quarter. Forum Financial Management LP bought a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at approximately $245,000. GF Fund Management CO. LTD. bought a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at approximately $156,000. Finally, MidWestOne Financial Group Inc. increased its holdings in shares of Jazz Pharmaceuticals by 10.4% during the fourth quarter. MidWestOne Financial Group Inc. now owns 24,347 shares of the specialty pharmaceutical company’s stock valued at $2,998,000 after acquiring an additional 2,284 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.